Biogen Inc has a consensus price target of $291.36 based on the ratings of 25 analysts. The high is $373 issued by Morgan Stanley on November 10, 2023. The low is $200 issued by Barclays on April 25, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Needham, and RBC Capital on July 12, 2024, June 28, 2024, and June 27, 2024, respectively. With an average price target of $308 between Piper Sandler, Needham, and RBC Capital, there's an implied 36.04% upside for Biogen Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/12/2024 | Buy Now | 38.25% | Piper Sandler | Christopher Raymond | $335 → $313 | Maintains | Overweight | Get Alert |
06/28/2024 | Buy Now | 29.86% | Needham | Ami Fadia | $294 → $294 | Reiterates | Buy → Buy | Get Alert |
06/27/2024 | Buy Now | 40.02% | RBC Capital | Brian Abrahams | $317 → $317 | Reiterates | Outperform → Outperform | Get Alert |
06/26/2024 | Buy Now | 40.02% | RBC Capital | Brian Abrahams | $317 → $317 | Reiterates | Outperform → Outperform | Get Alert |
06/05/2024 | Buy Now | 40.02% | RBC Capital | Brian Abrahams | $317 → $317 | Reiterates | Outperform → Outperform | Get Alert |
05/29/2024 | Buy Now | 40.02% | RBC Capital | Brian Abrahams | → $317 | Reiterates | Outperform → Outperform | Get Alert |
05/23/2024 | Buy Now | 32.51% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | Buy → Buy | Get Alert |
05/22/2024 | Buy Now | 29.86% | Needham | Ami Fadia | → $294 | Reiterates | Buy → Buy | Get Alert |
05/16/2024 | Buy Now | 50.18% | Truist Securities | Robyn Karnauskas | $340 → $340 | Maintains | Buy | Get Alert |
05/03/2024 | Buy Now | 51.06% | HSBC | Morten Herholdt | $339 → $342 | Maintains | Buy | Get Alert |
04/29/2024 | Buy Now | 19.26% | Oppenheimer | Jay Olson | $270 → $270 | Maintains | Outperform | Get Alert |
04/25/2024 | Buy Now | 29.86% | Needham | Ami Fadia | → $294 | Reiterates | Buy → Buy | Get Alert |
04/25/2024 | Buy Now | -11.66% | Barclays | Carter Gould | $215 → $200 | Maintains | Equal-Weight | Get Alert |
04/25/2024 | Buy Now | -5.04% | Wedbush | Laura Chico | $213 → $215 | Maintains | Neutral | Get Alert |
04/25/2024 | Buy Now | 32.51% | HC Wainwright & Co. | Andrew Fein | $325 → $300 | Maintains | Buy | Get Alert |
04/24/2024 | Buy Now | 29.86% | Needham | Ami Fadia | → $294 | Reiterates | Buy → Buy | Get Alert |
04/19/2024 | Buy Now | 19.26% | Oppenheimer | Jay Olson | $290 → $270 | Maintains | Outperform | Get Alert |
04/17/2024 | Buy Now | -5.48% | UBS | Colin Bristow | $250 → $214 | Maintains | Neutral | Get Alert |
04/17/2024 | Buy Now | -5.92% | Wedbush | Laura Chico | $245 → $213 | Maintains | Neutral | Get Alert |
04/12/2024 | Buy Now | 14.84% | B of A Securities | Geoff Meacham | $280 → $260 | Maintains | Neutral | Get Alert |
04/11/2024 | Buy Now | 6.01% | JP Morgan | Chris Schott | $270 → $240 | Maintains | Neutral | Get Alert |
04/04/2024 | Buy Now | -5.04% | Barclays | Carter Gould | $230 → $215 | Maintains | Equal-Weight | Get Alert |
03/25/2024 | Buy Now | 50.18% | Truist Securities | Robyn Karnauskas | → $340 | Reiterates | Buy → Buy | Get Alert |
03/05/2024 | Buy Now | 60.78% | RBC Capital | Brian Abrahams | → $364 | Reiterates | Outperform → Outperform | Get Alert |
02/22/2024 | Buy Now | 22.35% | Mizuho | Salim Syed | $355 → $277 | Maintains | Buy | Get Alert |
02/20/2024 | Buy Now | 37.37% | Cantor Fitzgerald | Eric Schmidt | → $311 | Reiterates | Overweight → Overweight | Get Alert |
02/20/2024 | Buy Now | 34.72% | Canaccord Genuity | Sumant Kulkarni | $310 → $305 | Maintains | Buy | Get Alert |
02/16/2024 | Buy Now | 10.42% | UBS | Colin Bristow | $276 → $250 | Maintains | Neutral | Get Alert |
02/14/2024 | Buy Now | 39.58% | Baird | Brian Skorney | $333 → $316 | Maintains | Outperform | Get Alert |
02/14/2024 | Buy Now | 43.55% | Piper Sandler | Christopher Raymond | $350 → $325 | Maintains | Overweight | Get Alert |
02/14/2024 | Buy Now | 25.88% | BMO Capital | Evan Seigerman | $295 → $285 | Maintains | Outperform | Get Alert |
02/14/2024 | Buy Now | 28.09% | Oppenheimer | Jay Olson | $295 → $290 | Maintains | Outperform | Get Alert |
02/14/2024 | Buy Now | 60.78% | RBC Capital | Brian Abrahams | $379 → $364 | Maintains | Outperform | Get Alert |
02/14/2024 | Buy Now | 6.01% | Wells Fargo | Mohit Bansal | $315 → $240 | Downgrade | Overweight → Equal-Weight | Get Alert |
02/14/2024 | Buy Now | 43.55% | HC Wainwright & Co. | Andrew Fein | → $325 | Reiterates | Buy → Buy | Get Alert |
02/14/2024 | Buy Now | 32.51% | Needham | Ami Fadia | $305 → $300 | Maintains | Buy | Get Alert |
02/13/2024 | Buy Now | 34.72% | Needham | Ami Fadia | → $305 | Reiterates | Buy → Buy | Get Alert |
01/30/2024 | Buy Now | 30.3% | Oppenheimer | Jay Olson | → $295 | Reiterates | Outperform → Outperform | Get Alert |
01/25/2024 | Buy Now | 21.91% | UBS | Colin Bristow | $311 → $276 | Downgrade | Buy → Neutral | Get Alert |
01/24/2024 | Buy Now | 21.91% | UBS | Colin Bristow | → $276 | Downgrade | Buy → Neutral | Get Alert |
12/20/2023 | Buy Now | 37.37% | Cantor Fitzgerald | Eric Schmidt | → $311 | Reiterates | Overweight → Overweight | Get Alert |
12/18/2023 | Buy Now | 30.3% | Oppenheimer | Jay Olson | $280 → $295 | Maintains | Outperform | Get Alert |
12/14/2023 | Buy Now | 26.77% | Stifel | Paul Matteis | $315 → $287 | Maintains | Buy | Get Alert |
12/07/2023 | Buy Now | 25% | Raymond James | Danielle Brill | → $283 | Upgrade | Market Perform → Outperform | Get Alert |
11/10/2023 | Buy Now | 64.75% | Morgan Stanley | Matthew Harrison | $361 → $373 | Maintains | Overweight | Get Alert |
11/09/2023 | Buy Now | 30.3% | BMO Capital | Evan Seigerman | $314 → $295 | Maintains | Outperform | Get Alert |
11/09/2023 | Buy Now | 60.34% | RBC Capital | Brian Abrahams | $351 → $363 | Maintains | Outperform | Get Alert |
11/09/2023 | Buy Now | 5.57% | Wedbush | Laura Chico | $266 → $239 | Maintains | Neutral | Get Alert |
11/09/2023 | Buy Now | 61.22% | Wells Fargo | Mohit Bansal | $343 → $365 | Maintains | Overweight | Get Alert |
10/26/2023 | Buy Now | 17.49% | Wedbush | Laura Chico | $270 → $266 | Maintains | Neutral | Get Alert |
10/26/2023 | Buy Now | 34.72% | Needham | Ami Fadia | → $305 | Reiterates | Buy → Buy | Get Alert |
10/11/2023 | Buy Now | 59.45% | Morgan Stanley | Matthew Harrison | $381 → $361 | Maintains | Overweight | Get Alert |
09/06/2023 | Buy Now | 59.01% | HSBC | Morten Herholdt | → $360 | Initiates | → Buy | Get Alert |
09/05/2023 | Buy Now | 68.29% | Morgan Stanley | Matthew Harrison | $363 → $381 | Maintains | Overweight | Get Alert |
08/29/2023 | Buy Now | 57.69% | RBC Capital | Brian Abrahams | $354 → $357 | Maintains | Outperform | Get Alert |
08/14/2023 | Buy Now | 47.97% | Mizuho | Salim Syed | $340 → $335 | Maintains | Buy | Get Alert |
08/08/2023 | Buy Now | 50.18% | Truist Securities | Robyn Karnauskas | $350 → $340 | Maintains | Buy | Get Alert |
08/08/2023 | Buy Now | 48.41% | BMO Capital | Evan Seigerman | $347 → $336 | Maintains | Outperform | Get Alert |
08/08/2023 | Buy Now | 29.86% | Barclays | Carter Gould | $311 → $294 | Maintains | Equal-Weight | Get Alert |
08/08/2023 | Buy Now | 34.72% | Needham | Ami Fadia | $323 → $305 | Maintains | Buy | Get Alert |
08/08/2023 | Buy Now | 21.47% | Atlantic Equities | Steve Chesney | $282 → $275 | Maintains | Neutral | Get Alert |
08/07/2023 | Buy Now | 56.36% | RBC Capital | Brian Abrahams | $374 → $354 | Maintains | Outperform | Get Alert |
08/07/2023 | Buy Now | 28.09% | Oppenheimer | Jay Olson | $360 → $290 | Maintains | Outperform | Get Alert |
08/07/2023 | Buy Now | 51.5% | Wells Fargo | Mohit Bansal | $350 → $343 | Maintains | Overweight | Get Alert |
07/31/2023 | Buy Now | 65.19% | RBC Capital | Brian Abrahams | $379 → $374 | Maintains | Outperform | Get Alert |
07/31/2023 | Buy Now | 42.67% | Needham | Ami Fadia | → $323 | Reiterates | Buy → Buy | Get Alert |
07/27/2023 | Buy Now | 44.43% | Scotiabank | George Farmer | → $327 | Initiates | → Sector Outperform | Get Alert |
07/26/2023 | Buy Now | 60.34% | Morgan Stanley | Matthew Harrison | $355 → $363 | Maintains | Overweight | Get Alert |
07/26/2023 | Buy Now | 67.4% | RBC Capital | Brian Abrahams | $341 → $379 | Maintains | Outperform | Get Alert |
07/26/2023 | Buy Now | 18.37% | Wedbush | Laura Chico | $269 → $268 | Maintains | Neutral | Get Alert |
07/26/2023 | Buy Now | 53.27% | BMO Capital | Evan Seigerman | $357 → $347 | Maintains | Outperform | Get Alert |
07/26/2023 | Buy Now | 43.55% | HC Wainwright & Co. | Andrew Fein | → $325 | Reiterates | Buy → Buy | Get Alert |
07/26/2023 | Buy Now | 42.67% | Needham | Ami Fadia | $320 → $323 | Maintains | Buy | Get Alert |
07/25/2023 | Buy Now | 41.34% | Stifel | Paul Matteis | $324 → $320 | Maintains | Buy | Get Alert |
07/25/2023 | Buy Now | 41.34% | Needham | Ami Fadia | → $320 | Reiterates | Buy → Buy | Get Alert |
07/11/2023 | Buy Now | 56.8% | Morgan Stanley | Matthew Harrison | $371 → $355 | Maintains | Overweight | Get Alert |
07/11/2023 | Buy Now | 50.62% | RBC Capital | Brian Abrahams | $332 → $341 | Maintains | Outperform | Get Alert |
07/07/2023 | Buy Now | 43.55% | HC Wainwright & Co. | Andrew Fein | → $325 | Reiterates | Buy → Buy | Get Alert |
07/07/2023 | Buy Now | 41.78% | Needham | Ami Fadia | → $321 | Reiterates | Buy → Buy | Get Alert |
06/12/2023 | Buy Now | 59.01% | Oppenheimer | Jay Olson | $350 → $360 | Maintains | Outperform | Get Alert |
06/12/2023 | Buy Now | 54.59% | Canaccord Genuity | Sumant Kulkarni | $330 → $350 | Maintains | Buy | Get Alert |
06/12/2023 | Buy Now | 41.78% | Needham | Ami Fadia | → $321 | Reiterates | Buy → Buy | Get Alert |
06/12/2023 | Buy Now | 43.55% | HC Wainwright & Co. | Andrew Fein | → $325 | Reiterates | Buy → Buy | Get Alert |
06/08/2023 | Buy Now | — | Barclays | Carter Gould | — | Maintains | Overweight | Get Alert |
06/08/2023 | Buy Now | 41.78% | Needham | Ami Fadia | → $321 | Reiterates | Buy → Buy | Get Alert |
06/07/2023 | Buy Now | 50.18% | Baird | Brian Skorney | → $340 | Reiterates | Outperform → Outperform | Get Alert |
06/02/2023 | Buy Now | 50.18% | RBC Capital | Brian Abrahams | → $340 | Reiterates | Outperform → Outperform | Get Alert |
06/01/2023 | Buy Now | 59.01% | Piper Sandler | Christopher Raymond | $346 → $360 | Maintains | Overweight | Get Alert |
05/23/2023 | Buy Now | 16.17% | Wedbush | Laura Chico | → $263 | Reiterates | Neutral → Neutral | Get Alert |
05/11/2023 | Buy Now | 54.59% | Argus Research | Jasper Hellweg | $320 → $350 | Maintains | Buy | Get Alert |
05/04/2023 | Buy Now | 41.34% | B of A Securities | Geoff Meacham | $300 → $320 | Maintains | Neutral | Get Alert |
05/01/2023 | Buy Now | 54.59% | Guggenheim | Yatin Suneja | $270 → $350 | Upgrade | Neutral → Buy | Get Alert |
04/26/2023 | Buy Now | 45.76% | Canaccord Genuity | Sumant Kulkarni | $325 → $330 | Maintains | Buy | Get Alert |
04/26/2023 | Buy Now | 50.18% | RBC Capital | Brian Abrahams | $344 → $340 | Maintains | Outperform | Get Alert |
04/26/2023 | Buy Now | 16.17% | Wedbush | Laura Chico | → $263 | Reiterates | → Neutral | Get Alert |
04/26/2023 | Buy Now | 43.55% | Oppenheimer | Jay Olson | $310 → $325 | Maintains | Outperform | Get Alert |
04/26/2023 | Buy Now | 43.55% | HC Wainwright & Co. | Andrew Fein | → $325 | Reiterates | → Buy | Get Alert |
04/26/2023 | Buy Now | 33.39% | Barclays | Carter Gould | $307 → $302 | Maintains | Equal-Weight | Get Alert |
04/26/2023 | Buy Now | 41.78% | Needham | Ami Fadia | $325 → $321 | Maintains | Buy | Get Alert |
04/26/2023 | Buy Now | 63.87% | Morgan Stanley | Matthew Harrison | $349 → $371 | Maintains | Overweight | Get Alert |
The latest price target for Biogen (NASDAQ:BIIB) was reported by Piper Sandler on July 12, 2024. The analyst firm set a price target for $313.00 expecting BIIB to rise to within 12 months (a possible 38.25% upside). 75 analyst firms have reported ratings in the last year.
The latest analyst rating for Biogen (NASDAQ:BIIB) was provided by Piper Sandler, and Biogen maintained their overweight rating.
The last upgrade for Biogen Inc happened on December 7, 2023 when Raymond James raised their price target to $283. Raymond James previously had a market perform for Biogen Inc.
The last downgrade for Biogen Inc happened on February 14, 2024 when Wells Fargo changed their price target from $315 to $240 for Biogen Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biogen was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.
While ratings are subjective and will change, the latest Biogen (BIIB) rating was a maintained with a price target of $335.00 to $313.00. The current price Biogen (BIIB) is trading at is $226.40, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.